Arrigo Capitanio

TL;DR: 25 spatially distinct regions from seven operable NSCLCs were sequenced and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification, and pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity.

TL;DR: A multi-omics survey of progressive compared to regressive carcinoma in situ lesions provides a molecular map of early lung cancer development and is expected to improve early detection, reduce overtreatment, and foster preventative therapies targeting early clonal events in lung cancer.

TL;DR: EBUS-TBNA is a safe, highly sensitive, and cost-saving initial investigation in patients with IML and is less costly than mediastinoscopy if the cost per EBUS- TBNA procedure is less than £2,718 ($4,307) per patient.

TL;DR: The aim of this study was to evaluate the feasibility, safety and efficacy of combined EBUS‐TBNA and standard bronchoscopic techniques in patients with suspected sarcoidosis and enlarged mediastinal or hilar lymphadenopathy.

TL;DR: In this article, the authors conducted a randomized trial to evaluate ERCC1 prospectively and to assess the superiority of non-platinum therapy over platinum doublet therapy in non-small-cell lung cancer (NSCLC) as well as noninferiority for ERCC 1-negative NSCLC.